Cardiac Allograft Vasculopathy Clinical Trial
— ACAVOfficial title:
ACAV: Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
Cardiac allograft vasculopathy (CAV) represents the leading cause of late morbidity and mortality in heart transplant recipients as the second most frequent cause of all deaths at 3 years. In distinction from general coronary atherosclerosis, CAV affects diffusely the entire coronary vasculature with marked intimal proliferation and concentric vascular thickening and fibrosis. It was demonstrated that most of the intimal thickening due to CAV occurs during the first year after transplantation. Furthermore, the severity of the CAV appears to correlate with lipid abnormalities and elevated low-density lipoprotein cholesterol (LDL-C) is very common after transplantation with nadir of LDL levels occurring at 6 months. Because of drug-drug interactions, heart transplant recipients cannot be treated with adequate doses of statins to achieve desirable reduction of LDL-C levels (reduction ˂ 60% of LDL-C). The use of alternative lipid-lowering drugs including bile acid sequestrates, fibrates, nicotinic acid or ezetimibe is not recommended in post-transplant scenario. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) increase availability has emerged as a novel drug tool for LDL-C lowering, capable to lower LDL-C by more than 60% even in statin-treated patients with very good safety profile. Although heart transplant recipients fulfill approved indication and standard clinical guidelines of a PCSK9 inhibitor, alirocumab, there are no available data on use of PCSK9 inhibitor in post-transplant situation. The purpose of the ACAV study is to clarify efficacy and safety of alirocumab compared to placebo administered during the first year after transplantation in heart transplant recipients in addition to background atorvastatin therapy. Except lipid profile, optical coherence tomography (OCT) will be performed as the objective efficacy endpoint to examine thickness and lumen of coronary vessels. It is expected that inhibition of PCSK9 in heart transplant recipient will dramatically improve post-transplant lipoprotein levels and perhaps slow down development of CAV in the most critical period of the first year after transplantation.
Status | Recruiting |
Enrollment | 126 |
Est. completion date | July 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. New cardiac transplant recipient = 18 years of age willing to participate in the study. 2. Ability to understand study procedures and to comply with them for the entire length of the study. 3. Written informed consent obtained from subject or subject's legal representative. 4. Heart transplantation surgery performed 3 - 8 weeks before the baseline visit. Exclusion Criteria: 1. Known hypersensitivity/allergy reaction to study medication. 2. Complicated post-transplant outcome with poor neurological status, multiorgan failure or graft dysfunction. 3. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 4. Lipoprotein apheresis is planned of performed. 5. Level of LDL-C = 8 mmol/L at screening. 6. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 7. Participation in any other interventional study. Known hypersensitivity/allergy to contrast agent or severe renal insufficiency (eGFR ? 30 mL/min/1.75 m2) exclude patient from OCT imaging only, not from the whole study. |
Country | Name | City | State |
---|---|---|---|
Czechia | Institute for Clinical and Experimental Medicine | Prague |
Lead Sponsor | Collaborator |
---|---|
Institute for Clinical and Experimental Medicine |
Czechia,
Chen Z, Pazdernik M, Zhang H, Wahle A, Guo Z, Bedanova H, Kautzner J, Melenovsky V, Kovarnik T, Sonka M. Quantitative 3D Analysis of Coronary Wall Morphology in Heart Transplant Patients: OCT-Assessed Cardiac Allograft Vasculopathy Progression. Med Image Anal. 2018 Dec;50:95-105. doi: 10.1016/j.media.2018.09.003. Epub 2018 Sep 14. — View Citation
Pazdernik M, Chen Z, Bedanova H, Kautzner J, Melenovsky V, Karmazin V, Malek I, Tomasek A, Ozabalova E, Krejci J, Franekova J, Wahle A, Zhang H, Kovarnik T, Sonka M. Early detection of cardiac allograft vasculopathy using highly automated 3-dimensional optical coherence tomography analysis. J Heart Lung Transplant. 2018 Aug;37(8):992-1000. doi: 10.1016/j.healun.2018.04.002. Epub 2018 Apr 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | calculated LDL cholesterol concentration | the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms | the time period between 2 and 12 months after heart transplantation | |
Primary | HDL cholesterol concentration | the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms | the time period between 2 and 12 months after heart transplantation | |
Primary | total cholesterol | the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms | the time period between 2 and 12 months after heart transplantation | |
Primary | triglycerides | the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms | the time period between 2 and 12 months after heart transplantation | |
Primary | ApoB | the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms | the time period between 2 and 12 months after heart transplantation | |
Primary | Lp (a) | the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms | the time period between 2 and 12 months after heart transplantation | |
Primary | Apo A1 | the difference in mean of values from visits 2, 3, 4 ,5 and 6 between alirocumab/placebo arms | the time period between 2 and 12 months after heart transplantation | |
Secondary | calculated LDL cholesterol concentration | Percent change from baseline (visit 1) to visit 6 between alirocumab/placebo arms | between 1 and 12 months after heart transplantation | |
Secondary | calculated LDL cholesterol concentration | Difference in values at every study visit between alirocumab/placebo arms | between 1 and 12 months after heart transplantation | |
Secondary | lipid parameters values | Difference in values at every study visit between alirocumab/placebo arms | between 1 and 12 months after heart transplantation | |
Secondary | calculated LDL cholesterol concentration | Difference in values at visit 6 compared to visit 7 between alirocumab/placebo arms | between 12 and 15 months after heart transplantation | |
Secondary | lipid parameters values | Difference in values at visit 6 compared to visit 7 between alirocumab/placebo arms | between 12 and 15 months after heart transplantation | |
Secondary | mean intimal thickness assessed by OCT | Percent change from baseline (visit 1) to visit 6 between alirocumab/placebo arms | 1 and 12 months after heart transplantation | |
Secondary | mean lumen volume assessed by OCT | Percent change from baseline (visit 1) to visit 6 between alirocumab/placebo arms | 1 and 12 months after heart transplantation | |
Secondary | incidence of adverse events | Assessment of safety of alirocumab in comparison to placebo | 1 and 15 months after heart transplantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02880137 -
Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
|
Phase 4 | |
Terminated |
NCT01848301 -
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
|
Phase 1 | |
Terminated |
NCT01278745 -
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
|
Phase 2 | |
Withdrawn |
NCT01812434 -
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
|
N/A | |
Withdrawn |
NCT01305382 -
Noninvasive Evaluation of Cardiac Allograft Vasculopathy
|
N/A | |
Recruiting |
NCT05826444 -
Microvascular Cardiac Allograft Vasculopathy Trial
|
||
Suspended |
NCT05756088 -
Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
|
||
Completed |
NCT02013037 -
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
|
Phase 3 | |
Withdrawn |
NCT01305395 -
Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
|
N/A | |
Withdrawn |
NCT01157949 -
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
|
Phase 3 | |
Enrolling by invitation |
NCT06147271 -
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT02798731 -
Physiologic Assessment of Microvascular Function in Heart Transplant Patients
|
||
Withdrawn |
NCT02777255 -
Severe CAV MRI in Heart Transplant Recipient
|
N/A | |
Completed |
NCT05373108 -
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
|
Phase 4 | |
Withdrawn |
NCT01424917 -
Noninvasive Predictors of Transplant Vasculopathy
|
N/A | |
Recruiting |
NCT04770012 -
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT01078363 -
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
|
N/A | |
Completed |
NCT03734211 -
Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
|
Phase 3 | |
Recruiting |
NCT06089486 -
MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation
|
N/A | |
Active, not recruiting |
NCT03386539 -
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
|
Phase 3 |